Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects

@article{Bolton2003EffectOR,
  title={Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects},
  author={Ann E. Bolton and Bin Peng and Martine Hubert and Axel J Krebs-Brown and Renaud Capdeville and Urs Keller and Michael K Seiberling},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2003},
  volume={53},
  pages={102-106}
}
This study was carried out to investigate the influence of CYP3A induction with rifampicin on imatinib (Gleevec) exposure. The study employed a single center, single-sequence design. A group of 14 healthy male and female subjects received imatinib as a single 400 mg oral dose on two occasions: on study day 1 and on study day 15. Rifampicin treatment (600 mg once daily) for CYP4503A induction was initiated on study day 8 and maintained until day 18. Imatinib pharmacokinetics were determined up… CONTINUE READING
53 Citations
12 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 53 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 12 references

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

  • GD Demetri, M Von Mehren, +18 authors H Joensuu
  • N Engl J Med
  • 2002
2 Excerpts

Similar Papers

Loading similar papers…